What differentiates Mesoblasts technology from that of its competitors?
Mesoblast’s technology ensures that its starting population of MPCs is more than 1000-fold purer than that of its competitors. Mesoblast’s MPCs have been shown in animal models to both create new blood vessels and stimulate cells at the site of damage to repair themselves, as well as providing functional cells to the region of tissue in need of repair. Because MPCs do not cause an immune reaction, MPCs for the treatment of different individuals can be grown from universal donors. This is not the case with other stem cell companies. Mesoblast is developing allogeneic (unrelated recipient) stem cell products for treatment of various medical conditions, including long bone fractures and degenerative intervertebral disc disease, both rapidly growing, billion dollar markets. In preclinical studies, Mesoblast’s stem cells have generated statistically superior long bone repair and spinal fusion compared with controls.
